| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 8, 2025 | Deep Bio’s AI Algorithm Demonstrates Significant Prognostic Advancements in Prostate Cancer Study | – AI-derived tumor volume metrics enhance prognostic prediction over traditional pathology methods SEOUL, SOUTH KOREA, April 8, 2025 /EINPresswire.com/ -- Deep Bio, a leader in AI-powered digital pathology, announced the publication of a gr... |
| Apr 2, 2025 | Deep Bio to Present Cutting-Edge AI-Powered Research in Digital Pathology at AACR 2025 | AI-driven biomarker quantification and cancer diagnostics research to be featured in multiple poster presentations SEOUL, SOUTH KOREA, April 2, 2025 /EINPresswire.com/ -- Deep Bio, a pioneer in AI-powered digital pathology, will present new... |
| Nov 19, 2024 | Deep Bio and PathAI Collaborate to Drive AI-Powered Innovations in Digital Pathology | – Integrating Deep Bio’s DeepDx Prostate Algorithm into PathAI’s AISight IMS Platform SEOUL, SOUTH KOREA, November 19, 2024 /EINPresswire.com/ -- Deep Bio, a leader in artificial intelligence for digital pathology, announced a collaboration... |
| Aug 6, 2024 | Deep Bio's AI Model for Prostate Cancer Assessment Validated by Researchers | SEOUL, SOUTH KOREA, August 6, 2024 /EINPresswire.com/ -- Deep Bio Inc., a leader in AI-driven digital pathology solutions, announced the publication of an external validation study for its DeepDx Prostate AI algorithm, conducted by Stanford... |
| May 21, 2024 | Deep Bio Unveils Research Findings on Performance Evaluation of AI Algorithm for Breast Cancer Analysis | Visual output of the Deep Bio MurSS model: Invasive ductal carcinoma is highlighted in red, while ambiguous areas are marked in purpl
Deep Bio utilizes deep learning-based algorithms to differentiate breast cancer lesions accurately, optimi... |
| Mar 19, 2024 | Deep Bio announces to present their research findings at the poster sessions during the USCAP 113th Annual Meeting | Four research results will be presented to validate Deep Bio’s pioneering research and breakthroughs in AI advancements in digital pathology. SEOUL, SOUTH KOREA, March 19, 2024 /EINPresswire.com/ -- Deep Bio, a leader in AI-driven solutions... |
| Jul 30, 2023 | Deep Bio Welcomes Grant Carlson as Chief Commercial Officer | SEOUL, South Korea (PRWEB) July 30, 2023
Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the appointment of Grant Carlson as its new Chief Commercial Officer (CCO). With over 30 years of experi... |
| Jul 7, 2023 | Deep Bio Secures Spot in South Korean Government's Prestigious "Super Gap Startup 1000+" Program | Seoul, Korea (PRWEB) July 07, 2023
Deep Bio Inc., a leader in artificial intelligence (AI)-powered cancer diagnostics, has been selected for the South Korean government's "Super Gap Startup 1000+" program. As a result of this sele... |
| May 12, 2023 | Deep Bio’s AI Algorithm Helps Risk Stratification for Prostate Cancer | Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that Dr. Lotan from Johns Hopkins Medicine presented their collaborative research which utilized the deep learning-based algorithm fo... |
| May 11, 2023 | Deep Bio’s AI Algorithm Helps Risk Stratification for Prostate Cancer | It is a meaningful milestone for Deep Bio to conduct a joint research with Johns Hopkins Medicine, one of the top global universities, and the findings are remarkable for prostate cancer diagnosis using AI
SEOUL, South Korea (PRWEB) May 11,... |
| Mar 15, 2023 | Deep Bio's Novel Study Results Reaffirm Its Global Presence | USCAP 2023 is Deep Bio's sixth consecutive year of presenting research abstracts
SEOUL, South Korea, March 14, 2023 /PRNewswire-PRWeb/ -- Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software shared... |
| Mar 14, 2023 | Deep Bio’s Novel Study Results Reaffirm Its Global Presence | It is inspiring that Deep Bio is presenting not only our own study but collaborative research abstract with reputable US CLIA laboratory ARUP at renowned international conferences
SEOUL, South Korea (PRWEB) March 14, 2023
Deep Bio, a pionee... |
| Nov 21, 2022 | Deep Bio and Visiopharm Announce a Collaborative Integration of a Clinical-Grade AI Prostate Cancer Solution with a Leading Digital Pathology Platform | Deep Bio, a leading AI biotech dedicated to cancer diagnosis, and Visiopharm, a world leader in AI-powered image analysis and tissue mining for research and diagnostics, announced a strategic partnership to provide pathologists access to th... |
| Nov 15, 2022 | Deep Bio and Visiopharm Announce a Collaborative Integration of a Clinical-Grade AI Prostate Cancer Solution with a Leading Digital Pathology Platform | Our dedication to AI for digital pathology has taken a major step forward with this collaboration and we are pleased to offer our latest technology to more labs and hospitals across the world through this opportunity.
SEOUL, South Korea (PR... |
| Oct 27, 2022 | Deep Bio Acquires ISO 27001 Certification for an Information Security Management | Achieving the certification proves our robust data security management systems. We will keep renewing this certification so that our partners and customers can use our AI-based cancer diagnostic support software with confidence.
SEOUL, Sout... |
| Oct 21, 2022 | Deep Bio Selected as ‘Korea AI Startup 100’ for Two Consecutive Years | with our innovative deep learning technology, we will strive to lead the digitalization of medical care
SEOUL, South Korea (PRWEB) October 21, 2022
Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support softw... |
| Oct 11, 2022 | Deep Bio Welcomes New Advisors to Accelerate Its Growth in Global Market | "With the remarkable advisors now joining Deep Bio, we will strive to establish our presence in the global market and bring innovative products to the industry."
SEOUL, South Korea (PRWEB) October 11, 2022
Deep Bio, a pioneer in m... |
| Oct 10, 2022 | Deep Bio’s AI Support for Prostate Cancer Diagnosis will be Deployed at Five Korean Hospitals | We are greatly expecting to prove that our software can be seamlessly integrated into the current pathology workflows, bringing positive changes such as reducing pathologists' work burden and improving efficiency in real clinical settings
S... |
| Aug 16, 2022 | Deep Bio Acquires MDSAP Certification, Paving the Way for Global Expansion | I am confident that passing the MDSAP audit can be a great opportunity to expand our presence in overseas markets.
SEOUL, South Korea (PRWEB) August 16, 2022
Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, announced tha... |
| Jul 25, 2022 | Deep Bio’s AI Support for Cancer Diagnosis has been Designated as an Innovative Product by the Korean Public Procurement Service | It represents an official government recognition of the innovation of our state-of-the-art technology. Through this, potential clients at national- and public institutions can better access Deep Bio’s groundbreaking software for purchase
SE... |
| May 13, 2022 | Deep Bio’s AI-based Cancer Diagnostic Software Demonstrated Uropathologist-level Performance | DeepDx® Prostate can provide value here, by providing consistent results to reduce discrepancies among pathologists, as well as reduce time spent on the reading of the slides, resulting in improved diagnostic accuracy and efficiency at the ... |
| Apr 11, 2022 | Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual Meeting 2022 | With the proven and tested technologies, we will lead digital pathology and AI through close partnerships with clinics, research institutes, and digital pathology platform providers
SEOUL, South Korea (PRWEB) April 11, 2022
Deep Bio, a pion... |
| Mar 23, 2022 | Deep Bio Presented Deep Learning-based Cancer Research at the USCAP 111th Annual Meeting | Sun Woo Kim, the CEO of Deep Bio said, "we will continue to endeavor in novel researches using our deep learning technology to bring innovations in cancer medicine.”
SEOUL, South Korea (PRWEB) March 23, 2022
Deep Bio, a pioneer in medi... |
| Nov 30, 2021 | Deep Bio and Tribun Health Join Forces to Enhance Cancer Care with AI-Powered Digital Pathology | We are confident that our software’s robust performance and Tribun Health’s extensive experience in digital pathology will not only add great diagnostic value but also address challenges pathologists are currently facing, one of which is th... |
| Nov 24, 2021 | Deep Bio Wins Approval for World’s First AI-based Prostate Cancer Severity Grading Software from Korea MFDS | It is deeply meaningful that Deep Bio introduces the world's first clearance of AI technology that aids grading the severity of prostate cancer in pathological tissue diagnosis.
SEOUL, South Korea (PRWEB) November 24, 2021
Deep Bio, a pione... |
| Oct 28, 2021 | Deep Bio Partners with Morphle Labs for Digital Pathology Image Analysis | Joining forces with India's leading scanner and digital pathology platform provider, our AI software will be accessible to a broader user base, especially in developing countries.
SEOUL, South Korea (PRWEB) October 28, 2021
Deep Bio, a pion... |
| Oct 25, 2021 | Deep Bio and ARUP to Conduct a Prospective Study to Evaluate AI Performance in a Real-World Pathology Workflow | This prospective study is significant in that it validates the overall performance of DeepDx® Prostate on real-world patient data
SEOUL, South Korea (PRWEB) October 25, 2021
Deep Bio, a leading company in AI cancer diagnostics, announced it... |
| Oct 18, 2021 | Deep Bio Inc. and HealthCare Konnect (HCK) Enter Into Partnership to Improve Cancer Diagnosis in Switzerland & North Africa | GENEVA, Switzerland (PRWEB) October 18, 2021
Healthcare Konnect, a Swiss medical device distribution company, and Deep Bio Inc., a South Korean leader in digital pathology and AI cancer diagnostics, entered into a distribution partnership t... |
| Oct 18, 2021 | Deep Bio’s Prostate Cancer Diagnostic Software Demonstrates High Concordance with Uropathologists at AUA 2021 | SEOUL, South Korea (PRWEB) October 18, 2021
Deep Bio, a pioneer in medical AI specialized for cancer diagnostics, announced that new study results on DeepDx® Prostate, Deep Bio’s deep learning-based prostate cancer diagnosis software, were ... |
| Aug 13, 2021 | Deep Bio’s AI-based Antibody Optimization Platform Applied to Parkinson’s Disease | “We are pleased to participate in a drug R&D for Parkinson’s disease where new treatment options are in need. Utilizing our AI-based algorithm will dramatically reduce the time and cost for drug optimization."
SEOUL, South Korea (P... |
| Aug 13, 2021 | Deep Bio’s AI-Based Antibody Optimization Platform Applied to Parkinson’s Disease | Collaborative research between Deep Bio and AngioLab for the development of a new mAb for PD
Deep Bio, a leading AI biotech dedicated to pathologic cancer diagnosis and prognosis, announced an on-going joint research with AngioLab, a Korean... |
| Jul 23, 2021 | Deep Bio Announces Research Collaboration with a Major Cancer Institute | If AI can serve as adjunct to human pathologists, the capacity for cancer diagnosis can improve significantly, particularly in regions such as Sub-Saharan Africa that are facing an extreme shortage of pathologists
SEOUL, South Korea (PRWEB)... |
| Jul 16, 2021 | Deep Bio Renews Software License Agreement with Stanford Medicine | We are proud to collaborate with Stanford Medicine and provide our AI diagnostic software to the research. We are excited that an algorithm such as DeepDx® Prostate which was trained on prostate core needle biopsy samples is being utilized ... |
| Jul 16, 2021 | Deep Bio Collaborates with ARUP in AI Clinical Implementation Research | I am confident that this partnership with the prestigious ARUP Laboratories will bring us closer to the end users as our brand awareness will increase overseas
SEOUL, South Korea (PRWEB) July 16, 2021
Deep Bio, a leading company in AI cance... |
